Hsiao-Jou Cortina Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hsiao-Jou Cortina Chen has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jereme G. Spiers
The Australian National University
22 shared publications Conrad Sernia
School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia
12 shared publicationsNickolas A. Lavidis
School of Biomedical Sciences, The University of Queensland, St Lucia, Queensland, 4072, Australia
12 shared publications- Florian Tobias Merkle
Institute of Metabolic Science - Metabolic Research Laboratories, University of Cambridge, Cambridge CB2 0QQ, UK
7 shared publications - Nickolas Anastasios Lavidis
School of Biomedical Sciences, The University of Queensland, St. Lucia, Brisbane 4072, Australia
5 shared publications Christine Rowley
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Regional Patterns of Neurodegeneration in a Mouse Model of Proteinopathy
The aggregation of misfolded proteins is a hallmark of many neurodegenerative diseases, suggesting shared pathological mechanisms. However, the pathways by which protein aggregation leads to neuronal death remain unclear. Proteinopathies can be modelled in transgenic animals by expressing disease-causing mutations that promote protein aggregation, or in wild-type animals by injecting misfolded proteins (e.g. RML scrapie) that spread in a prion-like manner and recapitulate key neurodegenerative features, including gliosis, ER stress, and neuronal loss. Here, we map the brain region-specific histopathological features of scrapie-induced neurodegeneration during early (12 weeks post-inoculation) and late (20 weeks) stages of disease. Using a streamlined protocol, we achieve reproducible paired sample collection and high-quality immunohistochemistry that is compatible with best practice in decontamination and containment. We found that among the tested markers of early pathology, thalamic astrocytic activation and spongiform degeneration were the most sensitive and that the thalamus and hippocampal CA1/CA3 areas exhibited the greatest pathological burden. By the later disease stage, there was widespread upregulation of IBA1+ microglia and GFAP+ astrocytes, accompanied by strong immunoreactivity of lysosomal marker LAMP1 that overlapped with GFAP+ immunoreactivity, suggesting astrocytic involvement in lysosomal pathology, in addition to neurons. Furthermore, the ER stress marker p-PERK was elevated in CA1/CA3 pyramidal neurons but minimal in the thalamus and cerebellum, where neuronal loss was most pronounced, suggesting region-specific mechanisms of degeneration. Overall, our shorter time-course, new safe handling protocols, and novel pathological insights support the broader adoption of the RML scrapie model for studies of neurodegeneration and its prevention.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRegional Patterns of Neurodegeneration in a Mouse Model of Proteinopathy
The aggregation of misfolded proteins is a hallmark of many neurodegenerative diseases, suggesting shared pathological mechanisms. However, the pathways by which protein aggregation leads to neuronal death remain unclear. Proteinopathies can be modelled in transgenic animals by expressing disease-causing mutations that promote protein aggregation, or in wild-type animals by injecting misfolded proteins (e.g. RML scrapie) that spread in a prion-like manner and recapitulate key neurodegenerative features, including gliosis, ER stress, and neuronal loss. Here, we map the brain region-specific histopathological features of scrapie-induced neurodegeneration during early (12 weeks post-inoculation) and late (20 weeks) stages of disease. Using a streamlined protocol, we achieve reproducible paired sample collection and high-quality immunohistochemistry that is compatible with best practice in decontamination and containment. We found that among the tested markers of early pathology, thalamic astrocytic activation and spongiform degeneration were the most sensitive and that the thalamus and hippocampal CA1/CA3 areas exhibited the greatest pathological burden. By the later disease stage, there was widespread upregulation of IBA1+ microglia and GFAP+ astrocytes, accompanied by strong immunoreactivity of lysosomal marker LAMP1 that overlapped with GFAP+ immunoreactivity, suggesting astrocytic involvement in lysosomal pathology, in addition to neurons. Furthermore, the ER stress marker p-PERK was elevated in CA1/CA3 pyramidal neurons but minimal in the thalamus and cerebellum, where neuronal loss was most pronounced, suggesting region-specific mechanisms of degeneration. Overall, our shorter time-course, new safe handling protocols, and novel pathological insights support the broader adoption of the RML scrapie model for studies of neurodegeneration and its prevention.
- Open Access
Regional patterns of neurodegeneration in a mouse model of proteinopathy
The aggregation of misfolded proteins is a hallmark of many neurodegenerative diseases, suggesting shared pathological mechanisms. However, the pathways by which protein misfolding in these proteinopathies lead to neuronal death remain unclear. Proteinopathies can be modelled in transgenic animals by expressing disease-causing mutations that promote protein aggregation, or in wild-type animals by injecting misfolded proteins (e.g. RML scrapie) that spread in a prion-like manner and recapitulate key neurodegenerative features, including gliosis, ER stress, and neuronal loss. Here, we map region-specific histopathological features of scrapie-induced neurodegeneration in the hippocampus, thalamus, cortex, and cerebellum during early (12 weeks post-inoculation) and late (20 weeks) stages of disease. Using a streamlined time-efficient protocol, we achieve reproducible paired sample collection and high-quality immunohistochemistry that is compatible with best practice in decontamination and containment. We found that among the tested markers of early pathology, thalamic astrocytic activation and spongiform degeneration were the most sensitive. By the late stage, there was widespread upregulation of IBA1 + microglia and GFAP + astrocytes, accompanied by strong immunoreactivity of lysosomal marker LAMP1. LAMP1 expression in healthy brains was largely neuronal, but by 20 weeks it was significantly upregulated in astrocytes, suggesting their involvement in lysosomal pathology. The ER stress marker p-PERK was elevated in CA1/CA3 pyramidal neurons but minimal in the thalamus and cerebellum, where neuronal loss was most pronounced, suggesting region-specific mechanisms of degeneration. Overall, the thalamus and hippocampal CA1/CA3 areas exhibited the greatest pathological burden. Our shorter time-course, new pathological insights and safe handling protocols, and improved welfare, supports broader adoption of the RML scrapie model for resource-efficient studies of neurodegeneration and its prevention.
Open AccessRegional patterns of neurodegeneration in a mouse model of proteinopathy
The aggregation of misfolded proteins is a hallmark of many neurodegenerative diseases, suggesting shared pathological mechanisms. However, the pathways by which protein misfolding in these proteinopathies lead to neuronal death remain unclear. Proteinopathies can be modelled in transgenic animals by expressing disease-causing mutations that promote protein aggregation, or in wild-type animals by injecting misfolded proteins (e.g. RML scrapie) that spread in a prion-like manner and recapitulate key neurodegenerative features, including gliosis, ER stress, and neuronal loss. Here, we map region-specific histopathological features of scrapie-induced neurodegeneration in the hippocampus, thalamus, cortex, and cerebellum during early (12 weeks post-inoculation) and late (20 weeks) stages of disease. Using a streamlined time-efficient protocol, we achieve reproducible paired sample collection and high-quality immunohistochemistry that is compatible with best practice in decontamination and containment. We found that among the tested markers of early pathology, thalamic astrocytic activation and spongiform degeneration were the most sensitive. By the late stage, there was widespread upregulation of IBA1 + microglia and GFAP + astrocytes, accompanied by strong immunoreactivity of lysosomal marker LAMP1. LAMP1 expression in healthy brains was largely neuronal, but by 20 weeks it was significantly upregulated in astrocytes, suggesting their involvement in lysosomal pathology. The ER stress marker p-PERK was elevated in CA1/CA3 pyramidal neurons but minimal in the thalamus and cerebellum, where neuronal loss was most pronounced, suggesting region-specific mechanisms of degeneration. Overall, the thalamus and hippocampal CA1/CA3 areas exhibited the greatest pathological burden. Our shorter time-course, new pathological insights and safe handling protocols, and improved welfare, supports broader adoption of the RML scrapie model for resource-efficient studies of neurodegeneration and its prevention.
- Open Access
Unbiased preclinical phenotyping reveals neuroprotective properties of pioglitazone
Animal models are essential for assessing the preclinical efficacy of candidate drugs, but animal data often fails to replicate in human clinical trials. This translational gulf is due in part to the use of models that do not accurately replicate human disease processes and phenotyping strategies that do not capture sensitive, disease-relevant measures. To address these challenges with the aim of validating candidate neuroprotective drugs, we combined a mouse prion (RML scrapie) model that recapitulates the key common features of human neurodegenerative disease including bona fide neuronal loss, with unbiased and machine learning-assisted behavioural phenotyping. We found that this approach measured subtle, stereotyped, and progressive changes in motor behaviour over the disease time course that correlated with the earliest detectable histopathological changes in the mouse brain. To validate the utility of this model system, we tested whether the anti-diabetic drug pioglitazone could slow prion disease progression. Pioglitazone crosses the blood-brain-barrier and has been shown to reduce neurodegenerative disease severity in other mouse models. We found that in addition to significantly slowing the emergence of early-stage clinical signs of neurodegeneration, pioglitazone significantly improved motor coordination throughout the disease time course and reduced neuronal endoplasmic reticulum stress. Together, these findings suggest that pioglitazone could have neuroprotective properties in humans, confirm the utility of the scrapie mouse model of neurodegeneration, and provide generalisable experimental and analysis methods for the generation of data-rich behavioural data to accelerate and improve preclinical validation.
Open AccessUnbiased preclinical phenotyping reveals neuroprotective properties of pioglitazone
Animal models are essential for assessing the preclinical efficacy of candidate drugs, but animal data often fails to replicate in human clinical trials. This translational gulf is due in part to the use of models that do not accurately replicate human disease processes and phenotyping strategies that do not capture sensitive, disease-relevant measures. To address these challenges with the aim of validating candidate neuroprotective drugs, we combined a mouse prion (RML scrapie) model that recapitulates the key common features of human neurodegenerative disease including bona fide neuronal loss, with unbiased and machine learning-assisted behavioural phenotyping. We found that this approach measured subtle, stereotyped, and progressive changes in motor behaviour over the disease time course that correlated with the earliest detectable histopathological changes in the mouse brain. To validate the utility of this model system, we tested whether the anti-diabetic drug pioglitazone could slow prion disease progression. Pioglitazone crosses the blood-brain-barrier and has been shown to reduce neurodegenerative disease severity in other mouse models. We found that in addition to significantly slowing the emergence of early-stage clinical signs of neurodegeneration, pioglitazone significantly improved motor coordination throughout the disease time course and reduced neuronal endoplasmic reticulum stress. Together, these findings suggest that pioglitazone could have neuroprotective properties in humans, confirm the utility of the scrapie mouse model of neurodegeneration, and provide generalisable experimental and analysis methods for the generation of data-rich behavioural data to accelerate and improve preclinical validation.
- Open Access
- 4 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (4) , 579-584
Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease
Obesity is a major risk factor for many common diseases and has a substantial heritable component. To identify new genetic determinants, we performed exome-sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We identified rare loss-of-function variants in two genes (BSN and APBA1) with effects substantially larger than those of well-established obesity genes such as MC4R. In contrast to most other obesity-related genes, rare variants in BSN and APBA1 were not associated with normal variation in childhood adiposity. Furthermore, BSN protein-truncating variants (PTVs) magnified the influence of common genetic variants associated with BMI, with a common variant polygenic score exhibiting an effect twice as large in BSN PTV carriers than in noncarriers. Finally, we explored the plasma proteomic signatures of BSN PTV carriers as well as the functional consequences of BSN deletion in human induced pluripotent stem cell-derived hypothalamic neurons. Collectively, our findings implicate degenerative processes in synaptic function in the etiology of adult-onset obesity.
- 4 April 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (4) , 579-584
Open AccessProtein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease
Obesity is a major risk factor for many common diseases and has a substantial heritable component. To identify new genetic determinants, we performed exome-sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We identified rare loss-of-function variants in two genes (BSN and APBA1) with effects substantially larger than those of well-established obesity genes such as MC4R. In contrast to most other obesity-related genes, rare variants in BSN and APBA1 were not associated with normal variation in childhood adiposity. Furthermore, BSN protein-truncating variants (PTVs) magnified the influence of common genetic variants associated with BMI, with a common variant polygenic score exhibiting an effect twice as large in BSN PTV carriers than in noncarriers. Finally, we explored the plasma proteomic signatures of BSN PTV carriers as well as the functional consequences of BSN deletion in human induced pluripotent stem cell-derived hypothalamic neurons. Collectively, our findings implicate degenerative processes in synaptic function in the etiology of adult-onset obesity.
- Open Access
- 20 December 2023
- Published by Springer Nature in EMBO Reports
- Vol. 25 (1) , 351-377
An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis
Hypothalamic Adult Neurogenesis (hAN) has been implicated in regulating energy homeostasis. Adult-generated neurons and adult Neural Stem Cells (aNSCs) in the hypothalamus control food intake and body weight. Conversely, diet-induced obesity (DIO) by high fat diets (HFD) exerts adverse influence on hAN. However, the effects of anti-obesity compounds on hAN are not known. To address this, we administered a lipidized analogue of an anti-obesity neuropeptide, Prolactin Releasing Peptide (PrRP), so-called LiPR, to mice. In the HFD context, LiPR rescued the survival of adult-born hypothalamic neurons and increased the number of aNSCs by reducing their activation. LiPR also rescued the reduction of immature hippocampal neurons and modulated calcium dynamics in iPSC-derived human neurons. In addition, some of these neurogenic effects were exerted by another anti-obesity compound, Liraglutide. These results show for the first time that anti-obesity neuropeptides influence adult neurogenesis and suggest that the neurogenic process can serve as a target of anti-obesity pharmacotherapy.
- 20 December 2023
- Published by Springer Nature in EMBO Reports
- Vol. 25 (1) , 351-377
Open AccessAn analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis
Hypothalamic Adult Neurogenesis (hAN) has been implicated in regulating energy homeostasis. Adult-generated neurons and adult Neural Stem Cells (aNSCs) in the hypothalamus control food intake and body weight. Conversely, diet-induced obesity (DIO) by high fat diets (HFD) exerts adverse influence on hAN. However, the effects of anti-obesity compounds on hAN are not known. To address this, we administered a lipidized analogue of an anti-obesity neuropeptide, Prolactin Releasing Peptide (PrRP), so-called LiPR, to mice. In the HFD context, LiPR rescued the survival of adult-born hypothalamic neurons and increased the number of aNSCs by reducing their activation. LiPR also rescued the reduction of immature hippocampal neurons and modulated calcium dynamics in iPSC-derived human neurons. In addition, some of these neurogenic effects were exerted by another anti-obesity compound, Liraglutide. These results show for the first time that anti-obesity neuropeptides influence adult neurogenesis and suggest that the neurogenic process can serve as a target of anti-obesity pharmacotherapy.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S383-S384
DYSREGULATED LIPID ACCUMULATION IN THE CORTEX AND LUMBAR CORD OF METABOLICALLY PERTURBED TDP-43Q331K-LOW MICE
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S383-S384
Open AccessDYSREGULATED LIPID ACCUMULATION IN THE CORTEX AND LUMBAR CORD OF METABOLICALLY PERTURBED TDP-43Q331K-LOW MICE
- Open Access
Metformin acts directly in the brain to slow features of neurodegeneration
Dementia is a largely untreatable syndrome that is epidemiologically associated with metabolic diseases such as type 2 diabetes (T2D) and obesity. Drugs used to treat T2D such as metformin are inexpensive, safely given to millions of people, and have also been reported to slow neurodegeneration. We hypothesised that the neuroprotective benefits of metformin might extend to metabolically healthy individuals and tested this hypothesis in a mouse prion model that recapitulates key features of human neurodegenerative disease, including synaptic loss and motor impairment. These features and the time course of this model (24 weeks) allows the effects of metabolic risk factors and metformin to be tested and potentially generalised to other forms of neurodegenerative disease. Mice fed a high fat diet (HFD) developed high adiposity with impaired glucose and insulin homeostasis, similar to the effects of chronic obesity seen in humans whereas mice on matched control diet (CD) remain metabolically healthy. Chronic treatment with metformin in HFD-fed mice significantly increased survival and health span relative to vehicle-treated mice. Mice fed a HFD also had a modestly extended health span relative to mice fed CD, as measured by development of motor signs of prion disease. Metformin also significantly extended health span in metabolically healthy CD-fed mice. Using targeted mass spectrometry, we found that metformin reached deep brain structures at functional concentrations, driving a reduction in pPERK and changing the activity of microglia in vivo . Metformin was able to alter ER stress pathways at the same concentrations in healthy animals and using human iPSC-derived microglia and mouse organotypic slices we show that the action of metformin at these concentrations does not require a systemic mechanism, necessary for the treatment of diabetes, and is likely a result of direct secondary pharmacology in the brain. Together, these data broadly support the premise of repurposing metformin for neuroprotection, even in metabolically healthy individuals.
Open AccessMetformin acts directly in the brain to slow features of neurodegeneration
Dementia is a largely untreatable syndrome that is epidemiologically associated with metabolic diseases such as type 2 diabetes (T2D) and obesity. Drugs used to treat T2D such as metformin are inexpensive, safely given to millions of people, and have also been reported to slow neurodegeneration. We hypothesised that the neuroprotective benefits of metformin might extend to metabolically healthy individuals and tested this hypothesis in a mouse prion model that recapitulates key features of human neurodegenerative disease, including synaptic loss and motor impairment. These features and the time course of this model (24 weeks) allows the effects of metabolic risk factors and metformin to be tested and potentially generalised to other forms of neurodegenerative disease. Mice fed a high fat diet (HFD) developed high adiposity with impaired glucose and insulin homeostasis, similar to the effects of chronic obesity seen in humans whereas mice on matched control diet (CD) remain metabolically healthy. Chronic treatment with metformin in HFD-fed mice significantly increased survival and health span relative to vehicle-treated mice. Mice fed a HFD also had a modestly extended health span relative to mice fed CD, as measured by development of motor signs of prion disease. Metformin also significantly extended health span in metabolically healthy CD-fed mice. Using targeted mass spectrometry, we found that metformin reached deep brain structures at functional concentrations, driving a reduction in pPERK and changing the activity of microglia in vivo . Metformin was able to alter ER stress pathways at the same concentrations in healthy animals and using human iPSC-derived microglia and mouse organotypic slices we show that the action of metformin at these concentrations does not require a systemic mechanism, necessary for the treatment of diabetes, and is likely a result of direct secondary pharmacology in the brain. Together, these data broadly support the premise of repurposing metformin for neuroprotection, even in metabolically healthy individuals.
- Open Access
Profiling human hypothalamic neurons reveals a candidate combination drug therapy for weight loss
Obesity substantially increases the risk of type 2 diabetes, cardiovascular disease, and other diseases, making it a leading preventable cause of death in developed countries. It has a strong genetic basis, with obesity-associated genetic variants preferentially acting in the brain. This includes the hypothalamic pro-opiomelanocortin (POMC) neurons that inhibit food intake and are stimulated by drugs that agonise glucagon-like 1 peptide receptor (GLP1R) including Semaglutide (Ozempic/Wegovy). We therefore hypothesised that drugs which selectively activate human POMC neurons would suppress appetite and promote weight loss, and that focusing on drugs already approved for use would facilitate rapid clinical translation. We therefore generated POMC neurons from human pluripotent stem cells (hPSCs) and identified enriched genes that were genetically associated with obesity and targeted by approved drugs. We found that human POMC neurons are enriched in GLP1R, reliably activated by Semaglutide, and their responses are further increased by co-administration of Ceritinib, an FDA-approved drug potently and selectively inhibiting anaplastic lymphoma kinase (ALK). Ceritinib reduced food intake and body weight in obese but not lean mice, and upregulated the expression of GLP1R in the mouse hypothalamus and hPSC-derived human hypothalamic neurons. These studies reveal a new potential therapeutic strategy for reducing food intake and body weight, and demonstrate the utility of hPSC-derived hypothalamic neurons for drug discovery.
Open AccessProfiling human hypothalamic neurons reveals a candidate combination drug therapy for weight loss
Obesity substantially increases the risk of type 2 diabetes, cardiovascular disease, and other diseases, making it a leading preventable cause of death in developed countries. It has a strong genetic basis, with obesity-associated genetic variants preferentially acting in the brain. This includes the hypothalamic pro-opiomelanocortin (POMC) neurons that inhibit food intake and are stimulated by drugs that agonise glucagon-like 1 peptide receptor (GLP1R) including Semaglutide (Ozempic/Wegovy). We therefore hypothesised that drugs which selectively activate human POMC neurons would suppress appetite and promote weight loss, and that focusing on drugs already approved for use would facilitate rapid clinical translation. We therefore generated POMC neurons from human pluripotent stem cells (hPSCs) and identified enriched genes that were genetically associated with obesity and targeted by approved drugs. We found that human POMC neurons are enriched in GLP1R, reliably activated by Semaglutide, and their responses are further increased by co-administration of Ceritinib, an FDA-approved drug potently and selectively inhibiting anaplastic lymphoma kinase (ALK). Ceritinib reduced food intake and body weight in obese but not lean mice, and upregulated the expression of GLP1R in the mouse hypothalamus and hPSC-derived human hypothalamic neurons. These studies reveal a new potential therapeutic strategy for reducing food intake and body weight, and demonstrate the utility of hPSC-derived hypothalamic neurons for drug discovery.
- Open Access
- 29 December 2021
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 85
Hepatic Homeostasis of Metal Ions Following Acute Repeated Stress Exposure in Rats
Essential metals such as copper, iron, and zinc are cofactors in various biological processes including oxygen utilisation, cell growth, and biomolecular synthesis. The homeostasis of these essential metals is carefully controlled through a system of protein transporters involved in the uptake, storage, and secretion. Some metal ions can be transformed by processes including reduction/oxidation (redox) reactions, and correspondingly, the breakdown of metal ion homeostasis can lead to formation of reactive oxygen and nitrogen species. We have previously demonstrated rapid biochemical responses to stress involving alterations in the redox state to generate free radicals and the resultant oxidative stress. However, the effects of stress on redox-active metals including iron and copper and redox-inert zinc have not been well characterised. Therefore, this study aims to examine the changes in these essential metals following exposure to short-term repeated stress, and to further elucidate the alterations in metal homeostasis through expression analysis of different metal transporters. Outbred male Wistar rats were exposed to unrestrained (control), 1 day, or 3 days of 6 h restraint stress (n = 8 per group). After the respective stress treatment, blood and liver samples were collected for the analysis of biometal concentrations and relative gene expression of metal transporter and binding proteins. Exposure to repeated restraint stress was highly effective in causing hepatic redox imbalance. Stress was also shown to induce hepatic metal redistribution, while modulating the mRNA levels of key metal transporters. Overall, this study is the first to characterise the gene expression profile of metal homeostasis following stress and provide insight into the changes occurring prior to the onset of chronic stress conditions.
- 29 December 2021
- Published by MDPI AG in Antioxidants
- Vol. 11 (1) , 85
Open AccessHepatic Homeostasis of Metal Ions Following Acute Repeated Stress Exposure in Rats
Essential metals such as copper, iron, and zinc are cofactors in various biological processes including oxygen utilisation, cell growth, and biomolecular synthesis. The homeostasis of these essential metals is carefully controlled through a system of protein transporters involved in the uptake, storage, and secretion. Some metal ions can be transformed by processes including reduction/oxidation (redox) reactions, and correspondingly, the breakdown of metal ion homeostasis can lead to formation of reactive oxygen and nitrogen species. We have previously demonstrated rapid biochemical responses to stress involving alterations in the redox state to generate free radicals and the resultant oxidative stress. However, the effects of stress on redox-active metals including iron and copper and redox-inert zinc have not been well characterised. Therefore, this study aims to examine the changes in these essential metals following exposure to short-term repeated stress, and to further elucidate the alterations in metal homeostasis through expression analysis of different metal transporters. Outbred male Wistar rats were exposed to unrestrained (control), 1 day, or 3 days of 6 h restraint stress (n = 8 per group). After the respective stress treatment, blood and liver samples were collected for the analysis of biometal concentrations and relative gene expression of metal transporter and binding proteins. Exposure to repeated restraint stress was highly effective in causing hepatic redox imbalance. Stress was also shown to induce hepatic metal redistribution, while modulating the mRNA levels of key metal transporters. Overall, this study is the first to characterise the gene expression profile of metal homeostasis following stress and provide insight into the changes occurring prior to the onset of chronic stress conditions.
- Open Access
- 25 October 2021
- Published by Springer Nature
Differentiation of hPSCs to hypothalamic neurons v2
This protocol is about Differentiation of hPSCs to hypothalamic neurons.
- 25 October 2021
- Published by Springer Nature
Open AccessDifferentiation of hPSCs to hypothalamic neurons v2
This protocol is about Differentiation of hPSCs to hypothalamic neurons.